tetano
Editor, Senior Moderator
Influenza Other Respir Viruses
. 2025 May;19(5):e70120.
doi: 10.1111/irv.70120. COVID-19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS-CoV-2 Infection Among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care Network
Charlotte Laniece Delaunay[SUP] 1 [/SUP], Nuno Verdasca[SUP] 2 [/SUP], Susana Monge[SUP] 3 [/SUP], Lisa Domegan[SUP] 4 [/SUP], Noémie Sève[SUP] 5 [/SUP], Silke Buda[SUP] 6 [/SUP], Adam Meijer[SUP] 7 [/SUP], Héloïse Lucaccioni[SUP] 1 [/SUP], Miriam López Torrijos[SUP] 8 [/SUP], Adele McKenna[SUP] 4 [/SUP], Vincent Enouf[SUP] 9 [/SUP], Ralf Dürrwald[SUP] 10 [/SUP], Eline In't Velt[SUP] 7 [/SUP], Mª Ángel de Valcárcel Laiglesia[SUP] 11 [/SUP], Charlene Bennett[SUP] 12 [/SUP], Shirley Masse[SUP] 13 [/SUP], Annika Erdwiens[SUP] 6 [/SUP], Mariette Hooiveld[SUP] 14 [/SUP], Ivan Mlinarić[SUP] 15 [/SUP], Gergő Túri[SUP] 16 [/SUP], Ana Paula Rodrigues[SUP] 17 [/SUP], Iván Martínez-Baz[SUP] 18 [/SUP], Mihaela Lazar[SUP] 19 [/SUP], Neus Latorre-Margalef[SUP] 20 [/SUP], Vitor Borges[SUP] 2 [/SUP], Marlena Kaczmarek[SUP] 21 [/SUP], Sabrina Bacci[SUP] 21 [/SUP], Esther Kissling[SUP] 1 [/SUP]; European primary care VE group
Affiliations
We estimated the effectiveness of 2024/25 COVID-19 vaccination against medically attended SARS-CoV-2 infection in Europe, among target groups. We included 3204 patients (8/139 cases vaccinated: 6%; 517/3065 controls vaccinated: 17%) from a multicentre, test-negative design study at primary care level. Vaccine effectiveness was 66% (95% CI: 34-85) overall, 73% (95% CI: 21-94) and 54% (95% CI: -3 to 83) in the first and second months post-vaccination, respectively. Overall vaccine effectiveness was 67% (95% CI: 33-86) among older adults (≥ 60 or ≥ 65 years). This relatively high COVID-19 VE (compared with previous seasons), as well as trends by time since vaccination, should be confirmed with additional data, as sample size was low.
Keywords: COVID‐19; Europe; SARS‐CoV‐2; vaccine effectiveness.
. 2025 May;19(5):e70120.
doi: 10.1111/irv.70120. COVID-19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS-CoV-2 Infection Among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care Network
Charlotte Laniece Delaunay[SUP] 1 [/SUP], Nuno Verdasca[SUP] 2 [/SUP], Susana Monge[SUP] 3 [/SUP], Lisa Domegan[SUP] 4 [/SUP], Noémie Sève[SUP] 5 [/SUP], Silke Buda[SUP] 6 [/SUP], Adam Meijer[SUP] 7 [/SUP], Héloïse Lucaccioni[SUP] 1 [/SUP], Miriam López Torrijos[SUP] 8 [/SUP], Adele McKenna[SUP] 4 [/SUP], Vincent Enouf[SUP] 9 [/SUP], Ralf Dürrwald[SUP] 10 [/SUP], Eline In't Velt[SUP] 7 [/SUP], Mª Ángel de Valcárcel Laiglesia[SUP] 11 [/SUP], Charlene Bennett[SUP] 12 [/SUP], Shirley Masse[SUP] 13 [/SUP], Annika Erdwiens[SUP] 6 [/SUP], Mariette Hooiveld[SUP] 14 [/SUP], Ivan Mlinarić[SUP] 15 [/SUP], Gergő Túri[SUP] 16 [/SUP], Ana Paula Rodrigues[SUP] 17 [/SUP], Iván Martínez-Baz[SUP] 18 [/SUP], Mihaela Lazar[SUP] 19 [/SUP], Neus Latorre-Margalef[SUP] 20 [/SUP], Vitor Borges[SUP] 2 [/SUP], Marlena Kaczmarek[SUP] 21 [/SUP], Sabrina Bacci[SUP] 21 [/SUP], Esther Kissling[SUP] 1 [/SUP]; European primary care VE group
Affiliations
- PMID: 40395132
- PMCID: PMC12093050
- DOI: 10.1111/irv.70120
We estimated the effectiveness of 2024/25 COVID-19 vaccination against medically attended SARS-CoV-2 infection in Europe, among target groups. We included 3204 patients (8/139 cases vaccinated: 6%; 517/3065 controls vaccinated: 17%) from a multicentre, test-negative design study at primary care level. Vaccine effectiveness was 66% (95% CI: 34-85) overall, 73% (95% CI: 21-94) and 54% (95% CI: -3 to 83) in the first and second months post-vaccination, respectively. Overall vaccine effectiveness was 67% (95% CI: 33-86) among older adults (≥ 60 or ≥ 65 years). This relatively high COVID-19 VE (compared with previous seasons), as well as trends by time since vaccination, should be confirmed with additional data, as sample size was low.
Keywords: COVID‐19; Europe; SARS‐CoV‐2; vaccine effectiveness.